156 related articles for article (PubMed ID: 23027885)
1. Annual medical costs and healthcare resource use in patients with systemic sclerosis in an insured population.
Furst DE; Fernandes AW; Iorga SR; Greth W; Bancroft T
J Rheumatol; 2012 Dec; 39(12):2303-9. PubMed ID: 23027885
[TBL] [Abstract][Full Text] [Related]
2. Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population.
Furst DE; Clarke A; Fernandes AW; Bancroft T; Gajria K; Greth W; Iorga SR
Lupus; 2013 Mar; 22(3):268-78. PubMed ID: 23340996
[TBL] [Abstract][Full Text] [Related]
3. Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population.
Furst DE; Clarke A; Fernandes AW; Bancroft T; Gajria K; Greth W; Iorga SR
J Med Econ; 2013; 16(4):500-9. PubMed ID: 23363329
[TBL] [Abstract][Full Text] [Related]
4. Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis.
Zhou Z; Fan Y; Thomason D; Tang W; Liu X; Zhou ZY; Macaulay D; Fischer A
Adv Ther; 2019 May; 36(5):1100-1113. PubMed ID: 30929184
[TBL] [Abstract][Full Text] [Related]
5. Medical costs and health-care resource use in patients with inflammatory myopathies in an insured population.
Furst DE; Amato AA; Iorga SR; Bancroft T; Fernandes AW
Muscle Nerve; 2012 Oct; 46(4):496-505. PubMed ID: 22987689
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of systemic sclerosis in a large US managed care population.
Furst DE; Fernandes AW; Iorga SR; Greth W; Bancroft T
J Rheumatol; 2012 Apr; 39(4):784-6. PubMed ID: 22382343
[TBL] [Abstract][Full Text] [Related]
7. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
8. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
9. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
10. Direct and indirect costs associated with Dupuytren's contracture.
Macaulay D; Ivanova J; Birnbaum H; Sorg R; Skodny P
J Med Econ; 2012; 15(4):664-71. PubMed ID: 22369346
[TBL] [Abstract][Full Text] [Related]
11. The cost to managed care of managing pulmonary hypertension.
Said Q; Martin BC; Joish VN; Kreilick C; Mathai SC
J Med Econ; 2012; 15(3):500-8. PubMed ID: 22313330
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
13. Cost of post-traumatic stress disorder vs major depressive disorder among patients covered by medicaid or private insurance.
Ivanova JI; Birnbaum HG; Chen L; Duhig AM; Dayoub EJ; Kantor ES; Schiller MB; Phillips GA
Am J Manag Care; 2011 Aug; 17(8):e314-23. PubMed ID: 21851139
[TBL] [Abstract][Full Text] [Related]
14. Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.
Kirson NY; Birnbaum HG; Ivanova JI; Waldman T; Joish V; Williamson T
Appl Health Econ Health Policy; 2011 Sep; 9(5):293-303. PubMed ID: 21875160
[TBL] [Abstract][Full Text] [Related]
15. Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States.
Zhou Z; Fan Y; Tang W; Liu X; Thomason D; Zhou ZY; Macaulay D; Fischer A
J Rheumatol; 2019 Aug; 46(8):920-927. PubMed ID: 30770505
[TBL] [Abstract][Full Text] [Related]
16. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy.
Wu EQ; Forsythe A; Guérin A; Yu AP; Latremouille-Viau D; Tsaneva M
Am J Ther; 2012 Nov; 19(6):e157-66. PubMed ID: 21317625
[TBL] [Abstract][Full Text] [Related]
17. Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population.
Kirson NY; Birnbaum HG; Ivanova JI; Waldman T; Joish V; Williamson T
Appl Health Econ Health Policy; 2011 Nov; 9(6):377-87. PubMed ID: 21888449
[TBL] [Abstract][Full Text] [Related]
18. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
19. The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder.
Asche CV; Joish VN; Camacho F; Drake CL
Curr Med Res Opin; 2010 Aug; 26(8):1843-53. PubMed ID: 20515321
[TBL] [Abstract][Full Text] [Related]
20. Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis.
Gayle A; Schoof N; Alves M; Clarke D; Raabe C; Das P; Del Galdo F; Maher TM
Adv Ther; 2020 May; 37(5):2460-2476. PubMed ID: 32319038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
